Table 1 Baseline demographics of study population (n = 28)

Demographics

Female, n (%)

19 (67.9)

Age, years, mean (SD)

57.4 (12.9)

BMI, kg/m2, mean (SD)

28.4 (7.4)

Alcohol, n (%)

15 (53.6)

Smoking (currently), n (%)

11 (39.3)

Prednisone, n (%)

11 (39.3)

Physiotherapy, n (%)

7 (25)

Disease duration (since diagnosis), years, median (IQR)

5.5 (11.3)

Laboratory results

CK [U/l], mean (SD)

252.9 (292.7)

AST [U/l], mean (SD)

35.3 (21.3)

ALT [U/l], mean (SD)

40.2 (54.4)

Physicial activity, health- and disease-related questionnaires

HAQ, 0–3 units, median (IQR)

0.875 (1.3)

SF-36, physical functioning, median (IQR)

65 (60)

Global disease activity score (0–10 NRS), median (IQR)

40 (58.5)

PHACO endurance, median (IQR)

7 (13)

PHACO strength, median (IQR)

10 (8)

TSK, median (IQR)

38 (9.5)

Physically active, n (%)

20 (71.4)

IPAQ total physical activity MET-min./week, median (IQR)

2544 (2778)

Muscle function

MMT8 (max.80), mean (SD)

69.8 (8.5)

MMT8 neck flexors, mean (SD)

9.25 (1.0)

MMT8 deltoid, mean (SD)

8.75 (1.3)

MMT8 biceps, mean (SD)

9.0 (1.0)

MMT8 gluteus maximus, mean (SD)

8.3 (1.5)

MMT8 gluteus medius, mean (SD)

7.7 (1.5)

MMT8 quadriceps, mean (SD)

8.8 (1.5)

MMT8 wrist extensors, mean (SD)

9.0 (1.0)

MMT8 ankle dorsiflexors, mean (SD)

9.1 (1.0)

Modified Barré test [sec.], mean (SD)

51.1 (15.2)

STS test [repetitions], mean (SD)

19.7 (6.4)

Mingazzini test [sec.], mean (SD)

44.6 (43.8)

Diagnoses

Dermatomyositis, n (%)

8 (28.6)

Antisynthetase syndrome, n (%)

9 (32.1)

Overlap myositis, n (%)

4 (14.3)

Polymyositis, n (%)

3 (10.7)

Interstitial myositis, n (%)

2 (7.1)

Necrotizing myopathy, n (%)

2 (7.1)

Spatiotemporal Gait Parameters

Walking speed [m/s2], mean (SD)

1.2 (0.2)

Walking cadence [steps/min], mean (SD)

107.7 (11.2)

Stride length [m], mean (SD)

1.3 (0.1)